muhammad zubair marwat
TRANSCRIPT
1
Enzyme Inhibition study of selected Schiff’s Bases
By Muhammad Zubair
M.Phil Scholar
2
SupervisorDr. Muhammad SajidAstt.ProfessorDepartment of Biochemistry
Co-SupervisorDr.Muhammad AshrafAssociate Professor Department Of Biochemistry & Biotechnology Bahawalpur
CONTENTS
INTRODUCTION.
EXPERIMENTAL.
RESULTS AND
DISCUSSIONS.
CONCLUSIONS.
ACKNOWLEDGEMENTS.
INTRODUCTION TO
ENZYME
4
Enzyme
5
Enzymes are protein molecules composed of amino acids ranging in 62 and 2,500 amino acid residues produced by the living cell. Enzymes are macromolecule which catalyse various chemical transformation in biological system.In a biological system enzyme control almost all essential function. In 1850s, Louis Pasteur revealed that in the presence of a catalyst called ‘’ferment’’ sugar could be fermented into alcohol by yeast. These molecule were called enzyme by Fredrick W.Kuhne. A breakthrough in early studies of enzyme were obtained when in 1926s, James Summer succeeded in isolation and crystallization of urease. In 1965s, D.C Phillips determined the lysozyme structure by single X-ray diffraction technique .
6
Lock and key theory
Theories of enzyme
Induced fit theory
7
Trypsin
Amylases
Cellulase
proteases, amylases
and lipases
Biological and Industrial Importance of Enzyme
Luciferase enzyme Muscle relaxation and
contraction
HIV integrase and reverse transcriptase
Various Enzyme their associated disease and specific inhibitor
Enzyme Associated disease Inhibitor(drug)
Carbonic anhydrase Glaucoma epilepsy Acetazolamide
Beta-glucoronidase Glaucoma d-saccharic acid 1,-4 lactone
Thymidine phosphorylase Cancer, Agiogenesis Endostatin
Alpha-glucosidase Diabetes Acarbose
Aldose reductase Eye and nerve damage in diabetes Atorvastatin and lovastatin
Reverse transcriptase Aids Zidovudine
Tyrosine kinase Carbonic myeloid leukaemia Tyrphostin
Propyl endopeptidase Cognitive disorder Peptidyl alpha –keto benzothiazole
Phosphodiestrase-4 Chronic obstructive pulmonary disease Rolipram
Lipoxygenase Asthama,inflammation Zileuton
Enzyme Associated disease Inhibitor(drug)
8
9
Types of enzyme inhibitors
Competitive inhibitor of enzymes
Non-competitive inhibitor of enzymes
Mix-Type inhibitor of enzymes
Uncompetitive inhibitor of enzymes
SCHIFF’S BASES
INTRODUCTION
10
Chemical compounds in which carbon-nitrogen have a double bond -C=N- and nitrogen atom is attached to aryl, alkyl, hetroaryl , hydrogen or lmetalo (usually Si, Al, B, Sn) are Schiff’s bases. These compounds were first synthesized and reported by Hugo Schiff.The Schiff bases general structure are as follow
11
CNR2
R1
R3
R1R2 and R3 = H, Alkyl or aryl1
Significance and application of Schiff’s bases
Schiff’s bases showed antipyretic, antiproliferative, antibacterial, antifungal, anti-inflammatory and antiviral activities. 1-amino-3-hydroxyguanidine tosylate-derived Schiff bases compound is most potent against mouse hepatitis virus (MHV).
Structure of antiviral drug
12
HO NHN
NH
NH
HO
.CH3C6H4SO3H
Antimalarial, 5-nitroisoquinolines
13
Antibacterial
Antifungal, Piperonyl
N
CF3
NO2
Cl
HO
NN
OHCl
N O
O
R
Introduction to HydrazoneHydrazone is a class of organic compounds and have a structure R1R2C=NNH2. Hydrazone are prepared by the action of hydrazine on ketone or aldehyde.
Biological activityHydrazone have a number of biological activity such as analgesic, anti-inflammatory and antiplatelet, antimalarial, antimicrobial, antitubercular, antitumoral, anticonvulsant and antidepressant activity
14
CR1
R2
NNH2
Biological active compoundsAnalgesic, 2-(2-formylfuryl) pyridylhydrazone
Antitumoral, Di-phenolic Hydrazone
15
N
HO
NH
NO2O2N
16
Alpha glucosidaseAlpha glucosidase enzyme (EC 3.2.1.20) is produced by mammalian small intestine. Alpha glucosidase remain bound to intestinal lining of the small intestine rather than secreted into the intestinal tract where it interacts with large carbohydrate taken in through the diet. Alpha-Glucosidase belongs to GH-family .Mechanism of action of alpha glucosidaseOne of the therapeutic approaches for reducing postprandial hyperglycaemia in patients with DM is to prevent absorption of carbohydrates after food uptake. Only monosaccharides, such as glucose and fructose, can be transported out of the intestinal lumen into the blood stream. Complex starches, oligosaccharides and disaccharides must be broken down into individual monosaccharides before being absorbed in the duodenum and upper jejunum. This digestion is facilitated by enteric enzyme, α-glucosidases that are attached to the brush border of the intestinal cells.
17
Alpha glucosidase
clinical inhibitor
VogliboseMiglitol
Acarbose
18
Introduction to Urease enzymeIn the history of science urease has a prominent place. James Sumner isolated and crystallized urease from Jack Bean plant (Carnavalia ensiformis) in 1926s.
For this achievement, he received noble prize in the field of chemistry in 1946s.Through his studies he confirmed that protein can be crystallized and also confirmed the proteinaceous nature of enzyme. Urease contain nickel in its active site .It belongs to amido-hydrolase family with (EC 3.3.1.5).Urease catalyse the decomposition of urea into ammonia and carbamate.It is a hydrolysis process. At the physiological pH carbamate hydrolyze spontaneously to carbonic acid and yield another molecule of ammonia. Urease is present in plant, fungi and various types of bacteria
19
Importance of urease in pathogenesis and agriculture
Peptic ulcer Urolithiasis Pyelonephritis
AmmoniaNitrogen cycle
20
Urease clinical inhibitor
Hydroxamic acid
Biscoumarin
Bismuth complexes
Phosphoramide
Imidazole
Aims and Objective
21
Due to its biological importance synthesized Schiff base were examined for enzyme inhibition such as α-glucosidase and urease enzyme.The alpha glucosidase has a role in Type 2 diabetes mellitus.Urease cause peptic ulcer,Dyspepsia,diarrhoea and kidney stone in human being and also causes agricultural problem. The present work is mainly concerned with drug development.
Experimental
22
SCHEMEThe Salicyloyl hydrazide Schiff bases synthesis were carried in two steps; firstly Salicyloyl hydrazide synthesis was done by treating methyl salicylate with hydrazine monohydrate in ethanol as a solvent with few drops of acetic acid for 4 hrs at room temp.The product in the first step were treated with different aldehydes (1:1) in EtOH at reflux for 2-3 hrs. HCl (1-2 drops) were added as a catalyst. The reaction progress was confirmed by TLC. The crude product were washed by ethyl alcohol and n-hexane to obtained pure Schiff bases.
23
24
HN
OHO
NH2
O
R H
O
NH
OHN
R
H H2OHClr.t
2-3hr
O
O
Me
HO HO
HN
O
NH2
Acetic Acid
r.t4hr
H2N-NH2.H2O Me-OH
SCHEME
Alpha Glucosidase assay
Percentage inhibition = 100 - (P.R – A.R / Abs of Control) × 100
25
70μL Buffer10μL test
compound10μL enzyme
Incubate for 10 minute
P.R at 400 nm
10μL substrate
A.R at 400nm
37 ºC
37 ºC
Incubate for 20 minute
26
37ºC
Incubate for 10 minute
P.R at 630 nm 15μL substrate
37ºCIncubate for 15 minute
40μL phenol& 60μL alkali
37ºCIncubate for 15 minute
A.R at 630
Percentage inhibition = 100 - (P.R – A.R / Abs of Control) × 100
urease assay65μL Buffer10μL test compound
10μL enzyme
Result and Discussion
27
Synthesis of various schiff,s base analogs 41-84
28
S. No R S. No R S. No R
41
47 53
42 48 54
43 49 55
44 50 56
45 51 57
46 52 58
29
S. No R S. No R S. No R
59
65 71
60 66 72
61 67 73
62 68 74
63 69 75
64 70 76
30
S. No R S. No R
77 83
78 84
79
80
81
82
31
S.No Inhibition (%) at
0.5 mM
IC50 ± SEMa (µM) S.No Inhibition (%) at
0.5 mM
IC50 ± SEMa (µM)
41 24.53±0.12 - 54 71.83±0.26 106.19±0.14
42 59.14±0.25 435.23±0.12 55 13.72±0.19 -
43 92.87±0.21 115.27±0.17 56 26.87±0.12 -
44 2.51±0.25 - 57 57.43±0.27 392.75±0.16
45 98.75±0.29 194.25±0.16 58 86.91±0.27 387.39±0.12
46 95.56±0.27 215.76±0.15 59 23.87±0.16 -
47 64.39±0.25 129.83±0.12 60 47.76±0.14 -
48 12.38±0.19 - 61 13.31±0.19 -
49 58.21±0.21 328.81±0.13 62 83.96±0.11 215.98±0.17
50 12.25±0.21 - 63 87.56±0.12 118.51±0.12
51 3.83±0.27 - 64 14.12±0.48 -
52 21.76±0.19 - 65 31.19±0.55 -
53 2.45±0.13 - Acarbose 92.23±0.14 38.25±0.12
Table showing alpha glucosidase inhibitory potential
Table showing alpha glucosidase inhibitory potential
S.No Inhibition (%) at 0.5
mM
IC50 ± SEMa (µM) S.No Inhibition (%) at 0.5
mM
IC50 ± SEMa (µM)
66 4.11±0.16 - 76 9.11±0.16 -
67 55.16±0.11 369.28±0.12 77 9.16±0.11 -
68 52.97±0.12 386.61±0.18 78 5.77±0.12 -
69 97.31±0.17 127.12±0.17 79 Amount less -
70 12.83±0.15 - 80 23.83±0.15 -
71 56.12±0.28 371.95±0.12 81 8.12±0.18 -
72 8.56±0.13 - 82 Amount less -
73 16.54±0.19 - 83 21.56±0.17 -
74 9.14±0.11 - 84 17.75±0.29 -
75 13.56±0.18 - Acarbose 92.23±0.14 38.25±0.12
32
SYNTHESIZED SALICYLOYL HYDRAZONE ALPHA
GLUCOSIDASE INHIBITIONCompound 54, with IC50 value (106.19±0.14) μM
43, with IC50 value (115.27±0.17) μM
63, with IC50 value (118.51±0.12) μM
69, with IC50 value (127.12±0.17 ) μM
47, with IC50 value (129.83±0.12 ) μM
Standard Acarbose with IC50 value (38.25±0.12)μM.
33
Table showing urease inhibitory potential
34
S. No.Inhibition (%)
at 0.5 mMIC50 (μM) S. No.
Inhibition (%)
at 0.5 mMIC50 (μM)
41 86.12±0.25 51.84±0.11 53 59.74±0.33 173.64±0.29
42 Amount less - 54 88.48±0.23 17.95±0.12
43 92.18±0.24 79.34±0.12 55 62.19±0.27 36.36±0.13
44 81.13±0.31 127.63±0.26 56 54.47±0.35 397.43±0.21
45 89.13±0.38 51.75±0.29 57 76.67±0.32 311.92±0.27
46 87.96±0.26 83.46±0.12 58 Amount less -
47 92.14±0.24 21.72±0.19 59 96.19±0.21 9.14±0.12
48 58.75±0.31 154.43±0.27 60 76.37±0.33 161.63±0.27
49 83.81±0.22 27.84±0.18 61 54.86±0.39 402.36±0.25
50 87.45±0.25 47.63±0.11 62 58.35±0.26 219.18±0.12
51 99.21±0.28 19.32±0.14 63 57.29±0.21 174.53±0.17
52 93.28±0.25 29.32±0.13 64 87.14±0.21 48.56±0.17
Table showing urease inhibitory potential
S. No.Inhibition (%) at
0.5 mMIC50 (μM) S. No.
Inhibition (%) at
0.5 mMIC50 (μM)
65 54.23±0.38 415.75±0.24 76 Amount less -
66 73.51±0.35 195.12±0.21 77 Amount less -
67 63.69±0.33 163.75±0.19 78 Amount less -
68 91.37±0.27 28.97±0.13 79 83.93±0.19 197.42±0.15
69 Amount less - 80 75.84±0.25 114.76±0.11
70 89.23±0.29 71.76±0.15 81 Amount less -
71 76.44±0.26 51.32±0.12 82 55.47±0.35 389.65±0.29
72 62.42±0.31 347.64±0.27 83 87.17±0.28 21.26±0.14
73 Amount less - 84 Amount less -
74 82.16±0.26 132.51±0.11 Standard (thiourea) 98.45±0.87 21.25±0.15
75 75.45±0.21 118.45±0.17
35
UREASE INHIBITION
Compound 47, with IC50 (21.72±0.19)μM
51, with IC50 (19.32±0.14)μM
54, with IC50 (17.95±0.12)μM
59, with IC50 (9.14±0.12 )μM
83, with IC50 (21.26±0.14 )μM
Standard Thiourea, with IC50 (21.25±0.15)μM
36
CONCLUSIONS
1. Present work was carried out for synthesis of salicyloyl hydrazone Schiff’s base analogs (41-84).
2. Compound were tested against α-Glucosidase and urease inhibition.
3. Results shows that all analogs show excellent to moderate potential.
37
ACKNOWLEDGEMENTSAlmighty Allah Dr. Muhammad Sajid (Supervisor) Dr. Muhammad Ashraf (Co-Supervisor) Associate Professor Islamia University BahawalpurProf. Dr. Mukhtiar Hassan (Chairman) Department Of Biochemistry.All Teachers My All Lab FellowsAll FriendsFamily Members
38
THANKS TO ALL OF
YOU39